Раковые клетки и раковые стволовые клетки

Douglas Hanahan, Robert A. Weinberg. Hallmarks of cancer: the next generation. Cell, Volume 144, Issue 5, p646–674, 4 March 2011

Cancer cells are the foundation of the disease; they initiate tumors and drive tumor progression forward, carrying the oncogenic and tumor suppressor mutations that define cancer as a genetic disease. Traditionally, the cancer cells within tumors have been portrayed as reasonably homogeneous cell populations until relatively late in the course of tumor progression, when hyperproliferation combined with increased genetic instability spawn distinct clonal subpopulations. Reflecting such clonal heterogeneity, many human tumors are histopathologically diverse, containing regions demarcated by various degrees of differentiation, proliferation, vascularity, inflammation, and/or invasiveness. In recent years, however, evidence has accumulated pointing to the existence of a new dimension of intratumor heterogeneity and a hitherto-unappreciated subclass of neoplastic cells within tumors, termed cancer stem cells (CSCs).

Although the evidence is still fragmentary, CSCs may prove to be a common constituent of many if not most tumors, albeit being present with widely varying abundance. CSCs are defined operationally through their ability to efficiently seed new tumors upon inoculation into recipient host mice. This functional definition is often complemented by including the expression in CSCs of markers that are also expressed by the normal stem cells in the tissue-of-origin.

CSCs were initially implicated in the pathogenesis of hematopoietic malignancies and then years later were identified in solid tumors, in particular breast carcinomas and neuroectodermal tumors. Fractionation of cancer cells on the basis of displayed cell-surface markers has yielded subpopulations of neoplastic cells with a greatly enhanced ability, relative to the corresponding majority populations, to seed new tumors upon implantation in immunodeficient mice. These often-rare tumor-initiating cells proved to share transcriptional profiles with certain normal tissue stem cell populations, motivating their designation as stem-like.

The origins of CSCs within a solid tumor have not been clarified and indeed may well vary from one tumor type to another. In some tumors, normal tissue stem cells may serve as the cells-of-origin that undergo oncogenic transformation to yield CSCs; in others, partially differentiated transit-amplifying cells, also termed progenitor cells, may suffer the initial oncogenic transformation thereafter assuming more stem-like character. Once primary tumors have formed, the CSCs, like their normal counterparts, may self-renew as well as spawn more differentiated derivatives; in the case of neoplastic CSCs, these descendant cells form the great bulk of many tumors. It remains to be established whether multiple distinct classes of increasingly neoplastic stem cells form during inception and subsequent multistep progression of tumors, ultimately yielding the CSCs that have been described in fully developed cancers.

Recent research has interrelated the acquisition of CSC traits with the EMT transdifferentiation program discussed above. Induction of this program in certain model systems can induce many of the defining features of stem cells, including self-renewal ability and the antigenic phenotypes associated with both normal and cancer stem cells. This concordance suggests that the EMT program not only may enable cancer cells to physically disseminate from primary tumors but also can confer on such cells the self-renewal capability that is crucial to their subsequent clonal expansion at sites of dissemination. If generalized, this connection raises an important corollary hypothesis: the heterotypic signals that trigger an EMT, such as those released by an activated, inflammatory stroma, may also be important in creating and maintaining CSCs.

An increasing number of human tumors are reported to contain subpopulations with the properties of CSCs, as defined operationally through their efficient tumor-initiating capabilities upon xenotransplantation into mice. Nevertheless, the importance of CSCs as a distinct phenotypic subclass of neoplastic cells remains a matter of debate, as does their oft-cited rarity within tumors. Indeed, it is plausible that the phenotypic plasticity operating within tumors may produce bidirectional interconversion between CSCs and non-CSCs, resulting in dynamic variation in the relative abundance of CSCs. Such plasticity could complicate definitive measurement of their prevalence. Analogous plasticity is already implicated in the EMT program, which can be engaged reversibly.

These complexities notwithstanding, it is evident that this new dimension of tumor heterogeneity holds important implications for successful cancer therapies. Increasing evidence in a variety of tumor types suggests that cells with properties of CSCs are more resistant to various commonly used chemotherapeutic treatments. Their persistence may help to explain the almost-inevitable disease recurrence following apparently successful debulking of human solid tumors by radiation and various forms of chemotherapy. Indeed, CSCs may well prove to underlie certain forms of tumor dormancy, whereby latent cancer cells persist for years or even decades after surgical resection or radio/chemotherapy, only to suddenly erupt and generate life-threatening disease. Hence, CSCs may represent a double-threat, in that they are more resistant to therapeutic killing and, at the same time, endowed with the ability to regenerate a tumor once therapy has been halted.

This phenotypic plasticity implicit in CSC state may also enable the formation of functionally distinct subpopulations within a tumor that support overall tumor growth in various ways. For example, an EMT can convert epithelial carcinoma cells into mesenchymal, fibroblast-like cancer cells that may well assume the duties of cancer-associated fibroblasts (CAFs) in some tumors. Remarkably, several recent reports have documented the ability of glioblastoma cells (or possibly their associated CSC subpopulations) to transdifferentiate into endothelial-like cells that can substitute for bona fide host-derived endothelial cells in forming a tumor-associated neovasculature. Observations like these indicate that certain tumors may acquire stromal support by inducing some of their own cancer cells to undergo various types of metamorphosis to produce stromal cell types rather than relying on recruited host cells to provide their functions.

The discovery of CSCs and biological plasticity in tumors indicates that a single, genetically homogeneous population of cells within a tumor may nevertheless be phenotypically heterogeneous due to the presence of cells in distinct states of differentiation. However, an equally important source of phenotypic variability may derive from the genetic heterogeneity within a tumor that accumulates as cancer progression proceeds. Thus, elevated genetic instability operating in later stages of tumor progression may drive rampant genetic diversification that outpaces the process of Darwinian selection, generating genetically distinct subpopulations far more rapidly than they can be eliminated.

Such thinking is increasingly supported by in-depth sequence analysis of tumor cell genomes, which has become practical due to recent major advances in DNA (and RNA) sequencing technology. Thus the sequencing of the genomes of cancer cells microdissected from different sectors of the same tumor has revealed striking intratumoral genetic heterogeneity. Some of this genetic diversity may be reflected in the long-recognized histological heterogeneity within individual human tumors. Alternatively, this genetic diversification may enable functional specialization, producing subpopulations of cancer cells that contribute distinct, complementary capabilities, which then accrue to the common benefit of overall tumor growth as described above.


Добавить комментарий

Войти с помощью: 

Ваш e-mail не будет опубликован. Обязательные поля помечены *